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ABSTRACT
Transcriptional elongation of most eukaryotic genes
by RNA polymerase II requires the kinase activity
of the positive transcription elongation factor b
(P-TEFb). The catalytically active P-TEFb complex
becomes inactive when sequestered into the large
complex by the cooperative actions of 7SK snRNA
and HEXIM1. In this study, we report that HEXIM1
forms oligomers in cells. This oligomerization is
mediated by its predicted coiled-coil region in the
C-terminal domain and 7SK snRNA that binds a
basic region within the central part of HEXIM1.
Alanine-mutagenesis of evolutionary conserved
leucines in the coiled-coil region and the digestion
of 7SK snRNA by RNase A treatment prevent this
oligomerization. Importantly, mutations of the
N-terminal part of the coiled-coil region abrogate
the ability of HEXIM1 to bind and inhibit P-
TEFb. Finally, the formation of HEXIM1 oligomers
via the C-terminal part of the coiled-coil or basic
regions is critical for the inhibition of transcription.
Our results suggest that two independent regions in
HEXIM1 form oligomers to incorporate P-TEFb into
thelargecomplexanddeterminetheinhibitionoftran-
scriptional elongation.
INTRODUCTION
Transcription of eukaryotic protein-coding genes by RNA
polymerase II (RNAPII) is tightly regulated at numerous
levels, which include the assembly of preinitiation com-
plexes, transcription initiation, promoter clearance, pausing,
elongation and termination (1). Studies of the regulation of the
human immunodeﬁciency virus (HIV) gene expression have
uncovered primarily the mechanisms that govern transcription
pausing and elongation (2). The transition to productive
elongation requires the positive transcription elongation factor
b (P-TEFb), which consists of heterodimers between a cata-
lytic subunit, the cyclin-dependent kinase 9 (Cdk9) and one of
the four C-type cyclin regulatory subunits, CycT1, CycT2a,
CycT2b or CycK (3). Upon its recruitment to the paused
RNAPII, P-TEFb phosphorylates serines at position 2 in the
C-terminal domain of the Rpb1 subunit of RNAPII, and
components of the negative transcription elongation factor
(N-TEF), which inactivates N-TEF and facilitates pre-
mRNA processing (1–4). P-TEFb is critical not only for pro-
ductive HIV gene expression, but is a general transcription
factor that is recruited to several cellular promoters and is
required for proper gene expression of most protein-coding
genes in human cells (5,6).
Recently, important aspects of the regulation of P-TEFb
have been revealed (2). Notably, P-TEFb exists in two
major forms in cells. The small complex (SC) is a heterodi-
meric complex and is catalytically active. In contrast, the large
complex (LC)is inactive and contains 7SK small nuclear RNA
(snRNA) and HEXIM1 or HEXIM2 (7–13). The inhibition of
P-TEFb is achieved by the cooperative actions of 7SK snRNA
and HEXIM1 or HEXIM2 (8,13). The binding between the
ﬁrst 175 nt of 7SK snRNA and the evolutionary conserved
basic region (BR) in HEXIM1 via its KHRR motif leads to
the interaction between the C- and N-terminal regions of
HEXIM1 and CycT1 or CycT2, respectively, resulting in
the inactivation of P-TEFb (8,9). The assembly of P-TEFb
into the LC can be prevented by disrupting the conserved
PYNT motif in HEXIM1 and HEXIM2 (7,8). On the other
hand, several stress-inducing agents and cardiac hypertrophic
signals disassemble the LC in cells (10,11,14,15). Interest-
ingly, diminution of HEXIM1 in HeLa cells results in the
incorporation of an otherwise free form of HEXIM2 into
*To whom correspondence should be addressed. Tel: +1 415 502 1902; Fax: +1 415 502 1901; Email: matija@itsa.ucsf.edu
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
7000–7010 Nucleic Acids Research, 2005, Vol. 33, No. 22
doi:10.1093/nar/gki997the large complex, demonstrating the dynamic and tightly
regulated nature of the assembly and disassembly of the
large complex (7,12).
Although several studies revealed aspects of the complex
assembly of the LC (7–9,12,13), and we presented data on
HEXIM1 homodimers and binding between the C-terminus in
HEXIM1 and CycT1 in vitro (16), no comprehensive analysis
of these RNA–protein and protein–protein interactions or their
functional correlates in vivo has been presented. To these ends,
we embarked on an extensive mutagenesis of HEXIM1,
deﬁned surfaces that form oligomers in the presence and
absence of 7SK snRNA as well as those that bind CycT1
and assemble the LC in cells. In addition, functional studies
of these mutant HEXIM1 proteins were performed on a plas-
mid target that depends uniquely on active P-TEFb complexes
(17). A model of the assembly of the LC is presented.
MATERIALS AND METHODS
Cell culture and cell lines
HeLa cells were grown in DMEM containing 10% fetal calf
serum at 37 C with 5% CO2.
Plasmids
The plasmid reporter pG6TAR and plasmid encoding
Gal.CycT1 protein were described (17). Plasmids coding
for f.Hex1, f.Hex1(1–278), f.Hex1(1–314) were a gift from
Dr H. Tanaka (18) and Q. Zhou (13). Plasmid f.Hex1mBR (as
well as other Hexim1 mutants carrying mBR) contains the
sequence of the SV-40 NLS at its N-terminus and was
described previously (19). To construct plasmids encoding
the mutant f.Hex1 proteins, the pFLAG-CMV2HEXIM1
plasmids were subjected to site-directed mutagenesis with
the QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). The plasmid encoding
f.Hex1mBR(1–315) was prepared according to the procedure
described previously (20). The plasmid coding for x.Hex1 was
made by cloning the cDNA of HEXIM1 into KpnI and ApaI
restriction sites of vector pcDNA3.1HisB (Invitrogen, Carls-
bad, CA). Hex1.CFP and Hex1.YFP constructs were created
by cloning of the wild-type HEXIM1 into pECFP-N1 and
pEYFP-N1 expression vectors (Clontech). To prepare plas-
mids encoding the mutant Hex1.CFP and Hex1.YFP proteins,
the Hex1.CFP and Hex1.YFP constructs were subjected to
site-directed mutagenesis with the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene). All plasmids coding
for Hex1.CFP and Hex1.YFP and carrying mB2 mutation
contain the sequence of the SV-40 NLS at its N-terminus
and were prepared as described previously (20).
Immunoprecipitation assay and western blot analysis
HeLa cells were grown on 100 mm plates. A total of 12 mgo f
plasmids were co-transfectedbytheFuGENE6reagent (Roche
Applied Science, Indianapolis, IN). After 40 h, HeLa cells
were harvested and lysed in 0.75 ml of lysis buffer [1%
NP-40, 10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 0.1% protease inhibitor and either 0.5% RNase inhib-
itor (Roche, Indianapolis, IN) or RNase A (100 mg/ml ﬁnal
concentration) (Qiagen, Hilden, Germany)] for 1 h at 4 C. The
lysates were immunoprecipitated with anti-FLAG M2
beads for 2–4 h at 4 C and bound proteins were separated
by SDS–PAGE electrophoresis and analyzed by immunoblot-
ting with appropriate antibodies.
Transient transfection and CAT assay
HeLa cells were grown on 60 mm plates. Subsequently 0.3 mg
of the pG6TAR reporter plasmid, 1 mg of Gal.CycT1 and
2.7 mg of appropriate f.Hex1 plasmid were co-transfected
by the FuGENE6 reagent. A CAT assay was performed as
described previously (17). In all transfections, the amount of
DNA was equilibrated with an empty vector. Fold transactiva-
tion represents the ratio between the Gal.CycT1 activated
transcription and the activity of the empty reporter plasmid
alone, which was given as one.
Immunoreagents
The mouse monoclonal anti-FLAG M2 antibody was obtained
from Sigma–Aldrich Corp. (St Louis, MO), the mouse mono-
clonal anti-Xpress antibody from Invitrogen and the goat poly-
clonal anti-CycT1 antibody (sc-8127) from Santa Cruz
Biotechnology (Santa Cruz, CA).
The rabbit anti-HEXIM1 antibody was generated against
HEXIM1 epitope LHRQQERAPLSKFGD and obtained
from Antibody Solutions (Mountain View, CA).
Coiled-coil prediction
The prediction of coiled-coil was performed on programs
available at the following addresses http://www.ch.embnet.
org/software/COILS_form.html and http://2zip.molgen.mpg.
de/cgi-bin/2zip.pl (21).
Fluorescence resonance energy transfer
(FRET) microscopy
HeLa cells were plated onto culture dishes containing a 25 mm
coverglass, transfected with the indicated expression plasmid
DNAs and subjected to ﬂuorescence microscopy 24 h post
transfections as described previously (22). Brieﬂy, the ﬂuor-
escence images were acquired using an inverted IX-70 Olym-
pus microscope using an Olympus ·40 Plan Apochromat
objective lens (Olympus Corp., Lake Success, NY). For
each cell, three ﬂuorescence channels were collected. The
donor channel consisted of CFP excited with 431–440 nm
light and CFP ﬂuorescence collected at 455–485 nm, the
acceptor channel consisted of YFP excited with 496–505
nm light and YFP ﬂuorescence collected at 520–550 nm,
and the FRET channel consisted of CFP excited with 431–
440 nm light and YFP ﬂuorescence collected at 520–550 nm.
Image collection and data analyses were conducted with Meta-
morph imaging software (Universal Imaging Corp.).
Glycerol gradient centrifugation
Glycerol gradients (10–30%) were established by pippeting
2 ml of each of the glycerol fractions (10, 15, 20, 25 and 30%
v/v) in buffer A (20 mM HEPES, pH 7.9, 0.3 M KCl, 0.2 mM
EDTA, 0.1% NP-40) into centrifugation tubes (Beckman, Palo
Alto, CA), catalog number 331372. Gradients were formed by
standing for 6 h at 4 C. HeLa cells either transfected with the
corresponding plasmids or not transfected were lysed in 0.5 ml
of buffer A containing 0.1% protease inhibitor and either 0.5%
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for 30 min at 4 C. The lysates were centrifuged at 10000 g
for 10 min and the supernatants were loaded into tubes with
the preformed glycerol gradients. Protein complexes were
then fractionated by centrifugation in an SW 41Ti rotor
(Beckman) at 38 000 r.p.m. for 21 h. Ten fractions (1 ml)
were collected, precipitated with trichloracetic acid and
ﬁnally analyzed by immunoblotting with the appropriate
antibodies (12).
RESULTS
Prediction of an evolutionary conserved CR in
the C-terminal domain of HEXIM1
To obtain further insight into the function of HEXIM1, we ﬁrst
performed multiple sequence alignments between human
HEXIM1 and HEXIM1 and HEXIM2 proteins from different
species. While the N-termini of HEXIM1 and HEXIM2 pro-
teins differ,the conserved regions include the centrallylocated
basic region (BR; positions 150 to 177 in the human HEXIM1
protein) and the C-terminal domain of the protein (Figure 1A).
We further analyzed C-terminal region in greater detail and
foundthatitcontainsseveral conserved clusters ofaminoacids
from position 279 to 339 in the human HEXIM1 protein
(Figure 1B). Among these, the consensus sequence indicated
a high number of conserved leucines. Notably, the leucines are
assembled in heptad repeats, which is the hallmark of coiled-
coil and oligomer-forming regions (23). Indeed, a prediction
program suggested a high probability for a coiled-coil in the
C-terminal domain of HEXIM1 from positions 279 to 352
(Figure 1C). Moreover, this analysis further indicated that
this CR could be composed of two parts. Its N-terminal
part from positions 279 to 315 could form a leucine zipper
and its C-terminal part from positions 319 to 352 could
constitute a coiled-coil. The highly conserved nature of the
C-terminus of HEXIM1 suggests its functional importance.
Finally, since it contains a predicted CR, we hypothesized
that HEXIM1 could form oligomers.
HEXIM1 forms oligomers in living cells
To test this hypothesis, we ﬁrst examined whether HEXIM1
proteins can interact with each other in living cells (Figure 2).
For these experiments, we used FRET microscopy. The effect-
ive energy transferbetweencyan (CFP)and yellow ﬂuorescent
protein (YFP) ﬂuorophores requires the two proteins to be 1–5
nM apart which typically corresponds to direct interaction of
proteins tagged with YFP and CFP. Thus, FRET imaging
provides the ability to monitor protein–protein interactions
in living cells and has also been recently used to detect protein
oligomerization (24–26). We fused the YFP and CFP to the
C-termini of different human HEXIM1 proteins, which resul-
ted in the construction of the hybrid Hex1.YFP and Hex1.CFP
proteins. Next, we expressed these chimeras individually or in
combination in HeLa cells and performed FRET microscopy.
When we co-expressed both chimeras, energy transfer resulted
in an increased FRET signal at the expense of the donor
emission (FRET/donor) relative to the cells expressing the
donor alone (Figure 2A, compare image i with c and f). Resid-
ual signal in the FRET channel of the images c and f represents
bleedthrough of the donor and acceptor channels to the FRET
channel, respectively. Similarly, when we plotted the FRET/
donor against the acceptor/donor ratios, we observed an
increase in the FRET signal with increasing amounts of
Figure 1. Prediction of CR1 and CR2 in the C-terminal domain of HEXIM1.
(A) Schematic depiction of human HEXIM1 protein (hHex1). White box
represents the BR. CR1 and CR2 are represented by black and gray boxes,
respectively. The numbering above the boxes defines the boundaries of the
regions. (B) Alignment of human (hHex1), mouse (mHex1), chicken (gHex1),
zebrafish (dHex1), fish (tHex1) HEXIM1 and human (hHex2) and mouse
(mHex2) HEXIM2 proteins. Black boxes indicate amino acid identity while
shaded boxes the amino acid similarity. The numbering above the alignment
corresponds to the boundaries of the predicted CR1 and CR2. Also, the num-
beredleucines,which aremarkedby anasterisk,weremutatedtoalanines.The
consensus sequence is indicated below the alignment. (C) The graph indicates
theprobabilityofcoiled-coilforthehumanHEXIM1proteinaspredictedbythe
coilspredictionprogram.Thelinebelowthegraphcorrespondstothesequence
of hHex1 and the boxes indicate regions with high probability of coiled-coil
(black box) and leucine zipper (white box) as predicted by the coils software.
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observed in cells that expressed the donor alone (Figure 2B).
Also, the levels of Hex1.YFP and Hex1.CFP proteins
were comparable and these fusion proteins inhibited
P-TEFb similarly to the wild-type HEXIM1 protein (data
not shown). As a negative control we used an irrelevant
protein, the class II transactivator (CIITA), fused to CFP
and Hex1.YFP. Co-expression of both chimeras resulted in
no FRET signal and no increase in the FRET signal
when we plotted the FRET/donor against the acceptor/
donorratios(datanotshown).Thus,HEXIM1proteinsinteract
with each other in living cells and consequently can form
oligomers.
The C-terminal domain of HEXIM1 and the 7SK
snRNA-bound BR direct HEXIM1 oligomerization
To deﬁne the regions that might form oligomers, we per-
formed immunoprecipitation assays (Figure 3). For these stud-
ies, we constructed a series of FLAG epitope-tagged HEXIM1
(f.Hex1) proteins, in which their C-termini were shortened
progressively (Figure 3A). While the mutant f.Hex1(1–314)
protein lacked the CR2, the mutant f.Hex1(1–278) and
f.Hex1(1–150) proteins lacked the entire CR. Also, except
for the mutant f.Hex1(1–150) protein, the rest of the proteins
contained the BR. Finally, we constructed an Xpress epitope-
tagged HEXIM1 (x.Hex1) protein. Next, we expressed the
f.Hex1 and x.Hex1 proteins in HeLa cells, immunoprecipit-
ated them from the total cell lysates using anti-FLAG agarose
beads and followed their binding by western blotting with
antibodies directed against the Xpress epitope. Consistent
Figure 2. HEXIM1 oligomerizes in the nucleus of cells. (A) Representative
images of Hex1.YFP and Hex1.CFP chimeras, which were expressed alone or
together in cells. Amounts of nuclear fluorescence were quantified in the
yellow, cyan and FRET channels. Energy transfer resulted in an increased
FRET at the expense of donor emissions (FRET/donor) in the co-expressing
cells relative to the cells containing the donors alone. (B) FRET/donor ratio
increasedproportionallywiththeamountoftheacceptorrelativetothedonorin
cells co-expressingHex1.YFPand Hex1.CFP chimeras.The slopeofthe graph
represents the extent of FRET at normalized acceptor/donor levels. There was
no FRET between Hex1.CFP proteins expressed alone.
Figure3.TheC-terminaldomainand7SKsnRNAmediatetheoligomerization
of HEXIM1. (A) Schematic diagram of Hex1 proteins used. The signs at their
N-termini depict the respective tags. (B) HEXIM1 forms oligomers. The
x.Hex1 and f.Hex1 proteins were either expressed alone (lanes 4 and 1, 2, 3,
8,respectively)orf.Hex1wasco-expressedwithx.Hex1inHeLacells(lanes5–
7 and 9) as indicated. Lysates were co-immunoprecipitated with anti-FLAG
agarose beads and immunoprecipitates of x.Hex1 were identified as presented
ontheupperwesternblot(WB).ThemiddleandlowerWBcontain10%ofinput
proteins for immunoprecipitations (IP). Wild-type and mutant HEXIM1 pro-
teins are identified by arrows. (C) 7SK snRNA and the C-terminal domain of
HEXIM1 mediate the oligomerization of HEXIM1. x.Hex1 was expressed
alone (lanes 1 and 2) or with the indicated f.Hex1 proteins (lanes 3–8). IP were
performed as in (B) and were treated with RNase A where indicated.
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protein bound x.Hex1 protein in cells (Figure 3B, lane 5).
The same result was obtained with the mutant f.Hex1(1–
314) protein (Figure 3B, lane 6). Surprisingly, the mutant
f.Hex1(1–278) protein retained the ability to bind x.Hex1
whereas the mutant f.Hex1(1–150) protein did not
(Figure 3B, lanes 7 and 9). Since the wild-type x.Hex1 protein
was not present in the anti-FLAG immunoprecipitations in the
absence of f.Hex1 protein (Figure 3B, lane 4) the binding
results were speciﬁc. These results suggest that in the absence
of the C-terminal domain of HEXIM1, BR is critical for the
formation of oligomers in HEXIM1. Furthermore, since 7SK
snRNA binds the BR in HEXIM1, we predicted that the BR
could mediate the oligomerization via 7SK snRNA.
To address this prediction directly and to assess the require-
ments of the C-terminal domain for HEXIM1 oligomerization,
we repeated the experiments described in Figure 3B and addi-
tionally performed parallel experiments in which we digested
7SK snRNA by treatment of the total cell lysates with RNase
A (Figure 3C). The wild-type f.Hex1 protein bound x.Hex1
protein in the presence of RNase A (Figure 3C, lanes 3 and 4).
This result corresponds with the recent ﬁndings that the full-
length HEXIM1 protein association does not change signiﬁc-
antly upon RNase A treatment (12). In contrast, RNase A
treatment disrupted the ability of the mutant f.Hex1(1–314)
and f.Hex1(1–278) proteins to bind x.Hex1 (Figure 3C, lanes
5–8). Also, levels of the f.Hex1 and x.Hex1 proteins in cell
lysates were comparable (Figure 3C, lower panel). Thus, the
oligomerization of HEXIM1 depends on the intact C-terminal
domain and the 7SK snRNA-bound BR.
Combined disruptions of the CR and 7SK snRNA
abolish HEXIM1 oligomerization
Next, we wanted to elucidate the importance of the predicted
CR in mediating HEXIM1 oligomerization (Figure 4). Since
the leucines within the heptad coiled-coil repeats are critical
for the coiled-coil structure and for the formation of oligomers
(21,23), we mutated a series of conserved leucines to alanines.
Alanine-mutagenesis was employed since non-polar alanines
maintain an a-helical structure of the region but prevent its
oligomerization capacity, which is mediated by the hydropho-
bic side chain methyl groups of the leucines. We mutated the
leucine doublets at positions 287 and 294 within the CR1 and
at positions 332 and 339 within the CR2 in the C-terminus of
HEXIM1 individually or in combination (Figure 4A). In this
way, we constructed the mutant proteins f.Hex1mCR1,
f.Hex1mCR2 and f.Hex1mCR12, respectively. Next, we
tested the ability of the wild-type and these mutant f.Hex1
proteins to oligomerize with the x.Hex1 protein by immuno-
precipitation in the presence or absence of RNase A as
described above. The wild-type and the mutant f.Hex1 pro-
teins bound x.Hex1 in the absence of RNase A (Figure 4B,
lanes 6, 8, 10 and 12). In contrast, the mutant f.Hex1mCR12
protein, in which both parts of the predicted CR were disrup-
ted, failed to bind x.Hex1 in the presence of RNase A
(Figure 4B, lane 7). However, the mutant f.Hex1 proteins
with individually disrupted coiled-coil parts bound x.Hex1
under the same conditions (Figure 4B, lanes 9 and 11).
Also, levels of the f.Hex1 and x.Hex1 proteins in cell lysates
were comparable (Figure 4B, lower panel). Thus, these results
indicate that the predicted CR directs HEXIM1 oligomeriza-
tion. Since the CR1 and CR2 mediate the formation of the
HEXIM1 oligomers by themselves in the context of the entire
C-terminus of HEXIM1, these two sequences could in prin-
ciple serve different functions.
To conﬁrm the results observed in immunoprecipitation
experiments, we decided toanalyzeoligomerizationproperties
of HEXIM1 mutants in living cells by FRET microscopy. We
constructed mutants of Hex1.YFP and Hex1.CFP with disrup-
ted oligomerization regions in the BR and in the C-terminal
domain of the protein. Mutants in the BR, where arginines
154–156 were mutated to alanines, were designated mB2
and represent the situation, where 7SK snRNA does not
bind to HEXIM1 (19). We prepared mutant Hex1mB2,
Hex1.mB2CR1 and Hex1.mB2CR12 as YFP and CFP fusion
proteins, where the 7SK snRNA binding site was disrupted
alone or in combination with disrupted CR1 and CR12,
respectively. Furthermore, we constructed Hex1.CR12 YFP
and CFP fusion proteins with disrupted CR but intact BR.
Next, we examined the ability of these mutant Hex1.CFP/
YFP proteins to interact with each other in living cells by
analyzing the FRET signal. Combined co-expression of
YFP and CFP fusion mutants, which carried at least one intact
oligomerization region resulted in a FRET signal (Figure 4C,
images c, f and i). In contrast, mutant Hex1.mB2CR12YFP/
CFP proteins with no functional oligomerization region
showed no FRET signal (Figure 4C, image l). Also, when
we plotted the FRET/donor against the acceptor/donor
ratios we observed an increase in the FRET signal with
increasing amounts of acceptor relative to donor with
mutant proteins with at least one functional oligomerization
region, but not with mutant proteins where all oligomerization
regions were disrupted (data not shown). We conclude that
combined disruptions of the CR and the 7SK snRNA binding
site abolish completely HEXIM1 oligomerization and that at
least one functional oligomerization domain is sufﬁcient to
mediate the formation of HEXIM1 oligomers in cells.
CR1 in HEXIM1 is required for its binding to P-TEFb
and inhibition of transcription
To explore the possibility that the CR1 and CR2 could be
functionally separable, we asked whether their individual dis-
ruptions could affect the binding to P-TEFb and thus inhibit
transcription differently (Figure 5). To accomplish this goal,
we ﬁrst expressed the wild-type f.Hex1 and the mutant
f.Hex1mCR1 and f.Hex1mCR2 proteins in HeLa cells and
performed immunoprecipitation assays as described above.
The presence of P-TEFb in the immunoprecipitations was
followed by western blotting with antibodies directed against
the endogenous CycT1 subunit of P-TEFb. As expected,
the wild-type f.Hex1 protein bound P-TEFb (Figure 5A,
lane 1) and the same was true for the mutant f.Hex1mCR2
protein (Figure 5A, lane 3). In contrast, the mutant
f.Hex1mCR1 protein decreased considerably its ability to
bind P-TEFb (Figure 5A, lane 2). Also, levels of f.Hex1
proteins were comparable (Figure 5A, lower panel). We
conclude that CR1 in HEXIM1 is critical for binding to
P-TEFb.
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Figure 4. Combined disruptions of the CR and BR abolish HEXIM1 oligomerization. (A) Schematic diagram of Hex1 proteins used. The sign at their N-termini
depicts the FLAG tag. The asterisks within the CR1 and CR2 indicate the mutations of leucines to alanines. The numbering indicates the positions of the mutated
leucinesinf.Hex1proteins.(B)HEXIM1withthedisruptedCRdoesnotoligomerizeintheabsenceof7SKsnRNA.ProteinswiththedisruptedCR1orCR2(lanes9–
12)orCR(lanes7and8)wereco-expressedwithx.Hex1inHeLacells.ThelysatesweretreatedwithRNaseAwhereindicated,immunoprecipitatedwithanti-FLAG
agarose beads and immunoprecipitates were subjected to SDS–PAGE and WB (upper panel). Lower panels represent 10% input of proteins. (C) Combined
disruptions of the CR and the 7SK snRNA binding site abolish completely HEXIM1 oligomerization in cells. FRET analysis was performed as in Figure 2.
RepresentativeimagesofthenucleiinwhichHex1.YFPandHex1.CFPmutantproteinswereco-expressedarepresented.Theamountsofnuclearfluorescencewere
quantified in the yellow, cyan and FRET channels.
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these f.Hex1 proteins to inhibit P-TEFb in a transcriptional
assay in HeLa cells (Figure 5B). We employed a system
consisting of a plasmid reporter pG6TAR, which contained
six Gal4 DNA-binding sites positioned upstream of the HIV
long terminal repeat, followed by the CAT reporter gene, and
a plasmid effector coding for the chimeric Gal.CycT1 protein.
Its recruitment to pG6TAR promoter activates transcription
and canbemeasuredby the CAT reporterassay (17).When we
co-expressed the Gal.CycT1 chimera with pG6TAR, levels
of CAT activity increased 27-fold over basal levels whereas
co-expression of the wild-type f.Hex1 protein decreased
this activity to 9-fold (Figure 5B, compare bars 1 and 2).
Strikingly, when we co-expressed the mutant f.Hex1mCR1
protein, this inhibitory function was lost (Figure 5B, bar 3).
In contrast, the mutant f.Hex1mCR2 protein inhibited P-TEFb
similarly to the wild-type f.Hex1 protein (Figure 5B, bar 4).
Levels of f.Hex1 proteins were comparable (Figure 5B, lower
panel). Also, the subcellular localization of both f.Hex1
mutants was the same as the wt f.Hex1 protein (data not
shown). Thus, it can be concluded that CR1 and CR2 are
functionally separable and only the CR1 in HEXIM1 is
required for the binding to P-TEFb, resulting in the inhibition
of its transcriptional activity.
Oligomerization of HEXIM1 via BR or CR2 is required
for the inhibition of transcription
To examine the functional importance of HEXIM1 oligomers,
we asked whether the ability of HEXIM1 to inhibit P-TEFb
depends on its oligomerization (Figure 6). We used the series
of f.Hex1 proteins presented in Figure 6A. The mutant
Figure 5. CR1 in HEXIM1is requiredfor itsbinding to P-TEFband inhibition
of transcription. (A) Disruption of the CR1 abrogates P-TEFb binding. f.Hex1
proteins were expressed in HeLa cells (6 mg, lanes 1–3) and immunoprecipi-
tated with anti-FLAG agarose beads. Amounts of bound endogenous CycT1 is
presentedbyWB(upperpanel).Theamountsoff.Hex1proteinsareindicatedin
WBbelow(lowerpanel).(B)f.Hex1mCR1doesnotinhibittranscription.HeLa
cells expressed pG6TAR (0.3 mg), Gal.CycT1 (1 mg) and f.Hex1 (2.7 mg) as
depicted. Bars correspond to CAT values and the lower panel presents expres-
sion (WB) of f.Hex1 as indicated by the arrow.
Figure 6. Oligomerization of HEXIM1 via its BR or CR2 is required for the
inhibition of transcription. (A) Schematic diagram of Hex1 proteins used. The
BR, CR1 and CR2 regions participating in the oligomerization are depicted.
Thewild-typeandthemutatedresiduesoftheBRaredepictedaboveandbelow
the diagram, respectively. The mutated BR is indicated by asterisk. The sche-
maticpicturerepresentsthef.Hex1andmutantf.Hex1(1–314),f.Hex1mBRand
f.Hex1mBR(1–315) proteins used. (B) HEXIM1 without the BR and the CR2
does not oligomerize. The x.Hex1 and f.Hex1 proteins were co-expressed as
depicted.LysatesweretreatedwithRNaseAwherenotedandIPwasperformed
as described. Upper panel represents WB with the immunoprecipitated x.Hex1
proteins,whereasthemiddleandlowerpanelsshow10%inputofproteinsused
forIP.(C)HEXIM1withouttheBRandtheCR2doesnotinhibitP-TEFb.Bars
represent CAT data obtained by co-transfection of HeLa cells with pG6TAR
(0.3 mg), Gal.CycT1 (1 mg) and indicated f.Hex1 plasmids (2.7 mg). The lower
panel presents the expression of f.Hex1 proteins.
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sess oneortworegions thatform oligomers,respectively,were
described above. Two additional mutant f.Hex1 proteins were
constructed. The mutant f.Hex1mBR protein, in which most of
the basic residues in the BR were mutated to alanines, contains
a disrupted BR. It does not bind 7SK snRNA in vitro, but
inhibits P-TEFb in transcriptional assays (19). Finally, the
mutant f.Hex1mBR(1–315) has a disrupted BR and CR2.
Both of these mutant proteins also contain the SV-40 NLS,
which enables their nuclear localization. To examine the oli-
gomerization of these f.Hex1 proteins, we performed immuno-
precipitation assays in the presence or absence of RNase A
(Figure 6B). As already presented in Figure 3 and in the recent
report (12), the RNase A treatment did not change consider-
ably the binding between the wild-type f.Hex1 and x.Hex1
proteins (Figure 6B, lanes 3 and 4) but it prevented the binding
with the mutant f.Hex1(1–314) protein (Figure 6B, lanes 5 and
6). Predictably, the mutant f.Hex1mBR protein with the intact
CR bound x.Hex1 independently of RNase A treatment
(Figure 6B, lanes 9 and 10). In contrast, the mutant
f.Hex1mBR(1–315), which lacks the CR2 and the BR, failed
to bind x.Hex1 in the presence or absence of RNase A
(Figure 6B, lanes 7 and 8). Levels of f.Hex1 and x.Hex1
proteins in cell lysates were comparable (Figure 6B, lower
panel). The result in Figure 6B, lane 5, may seem to contradict
the result obtained with the immunoprecipitation of mutant
f.Hex1mCR2 under RNase A treatment where oligomers were
observed (Figure 4B, lane 11). However, it is important to note
that in the mutant f.Hex1mCR2 protein just two C-terminally
located leucines were mutated in comparison with the deletion
of the entire CR2 in the f.Hex1(1–314).
Finally, to determine whether the oligomerization of
HEXIM1 correlates with its inhibitory function, we assessed
the abilities of these f.Hex1 proteins to inhibit P-TEFb by
using transcriptional assays in HeLa cells (Figure 6C). We
employed the same system as described in Figure 5. The
wild-type f.Hex1 protein decreased the activity of the Gal.-
CycT1 chimeric protein from 29- to 9-fold over the basal
levels (Figure 6C, compare bars 1–3). Similarly, the mutant
f.Hex1(1–314) and f.Hex1mBR proteins inhibited P-TEFb
equivalently to the wild-type f.Hex1 protein (Figure 6C,
bars 4 and 5). Critically, the mutant f.Hex1mBR(1–314) pro-
tein, which could not form oligomers, failed to inhibit P-TEFb
(Figure 6C, bar 6). Thus, the separate disruption of two oli-
gomerization domains does not affect the abilities of these
mutant HEXIM1 proteins to inhibit P-TEFb. Rather, the com-
bined disruption of the BR and the CR2 prevents not only the
formation of oligomers, but also the inhibition of transcrip-
tional activity of P-TEFb. We conclude that the ability of
HEXIM1 to inhibit P-TEFb requires its oligomerization.
Oligomerization of HEXIM1 via BR or CR2 is required
for the incorporation of HEXIM1 into the LC
To conﬁrm these results, we correlated the inhibitory function
of f.Hex1 proteins with their ability to bind P-TEFb and to
incorporate into the LC (Figure 7). We hypothesized that
mutant f.Hex1 proteins, which do not inhibit P-TEFb, also
do not bind it. For this purpose, we expressed our mutant
f.Hex1 proteins and performed immunoprecipitation assays
as described (Figure 7A). The presence of P-TEFb in the
immunoprecipitations was followed by western blotting with
antibodies directed against the endogenous CycT1 subunit of
P-TEFb. The wild-type f.Hex1 protein bound P-TEFb
(Figure 7A, lane 2) and the lysate from the mock transfected
cell did not (Figure 7A, lane 1). As predicted, the mutant
f.Hex1(1–314) and f.Hex1mBR proteins with only one disrup-
ted oligomerization region, which inhibited P-TEFb, also
bound P-TEFb (Figure 7A, lanes 3 and 4), although
f.Hex1mBR shown reduced binding in comparison with
f.Hex1. In contrast, the mutant protein f.Hex1mBR(1–315)
did not interact with P-TEFb at all, which corresponds well
with its abrogated inhibitory function (Figure 7A, lane 5). The
levels of f.Hex1 proteins were comparable (Figure 7A, lower
panel). Thus, the loss of the inhibitory function of the mutant
Hex1 protein with the combined disruption of BR and CR2 is
due to its inability to bind P-TEFb.
Part of the P-TEFb in HeLa cells is incorporated into func-
tionally inactive LC. The rest of P-TEFb is catalytically active
Figure 7. Oligomerization of HEXIM1 via BR or CR2 is required for the
incorporationofHEXIM1intothe LCofP-TEFb.(A) HEXIM1withdisrupted
BR and CR2 does not bind P-TEFb. HeLa cells were either mock transfected
(lane 1) or transfected with f.Hex1 plasmids (6 mg, lanes 2–5). The f.Hex1
proteinswere immunoprecipitatedwithanti-FLAG agarosebeads. Amountsof
bound endogenous CycT1 is presented by WB (upper panel). The amounts of
f.Hex1 proteins are indicated in WB below (lower panel). (B) HEXIM1 with
disrupted BR and CR2 does not incorporate into the LC. Lysates from either
mock or f.Hex1 plasmids transfected cells were divided into ten fractions by
glycerol gradient centrifugation. Amounts of endogenous HEXIM1 proteins in
each fraction were analyzed by immunoblotting as shown on the panels. The
numbers below and above panels depict the glycerol fractions and arrow
indicates increasing glycerol gradient (from 10 to 30%). SC and LC stand
for small complex and large complex of the P-TEFb, respectively.
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combined disruption of BR and CR2 neither inhibits nor binds
P-TEFb, we hypothesized that these two regions are critical
for the incorporation of HEXIM1 into the LC. To prove this
assumption, we employed glycerol gradient centrifugation of
lysates from HeLa cells that expressed different mutant f.Hex1
proteins and analyzed the ability of these mutants to form LC
with endogenous P-TEFb (Figure 7B). As a control, we
observed endogenous HEXIM1 proteins in SC and LC in
lysates of the mock transfected cells (Figure 7B, upper two
panels). Upon treatment with RNase A, HEXIM1 was released
from the LC and was found only in the free form. Sub-
sequently, we expressed wild-type and mutant f.Hex1 proteins
with either separately disrupted BR and CR2 or in combina-
tion. As expected, the wild-type f.Hex1 and mutant f.Hex(1–
314) and f.Hex1mBR proteins, which oligomerize and inhibit
P-TEFb, were also incorporated into the LC. In contrast, the
mutant f.Hex1mBR(1–315) protein existed only in the free
form and failed to be incorporated into the LC (Figure 7B,
compare four lower panels), which is consistent with its inab-
ility to inhibit P-TEFb. Thus, we conclude that the BR and
CR2 regions are required for oligomerization and incorpora-
tionofHEXIM1intothe LCtodirectthe inhibitionof P-TEFb.
DISCUSSION
In this study, we investigated mechanisms dictating the assem-
bly of the 7SK snRNA:HEXIM1:P-TEFb complex that inhib-
its transcriptional elongation. First, a predicted CR was found
in the C-terminus of HEXIM1. Second, HEXIM1 forms oli-
gomers via this CR and BR that binds 7SK snRNA in cells.
Third, in the presence of 7SK snRNA, the CR1 binds P-TEFb
whereas the CR2 mediates HEXIM1 oligomerization. Finally,
we determined that the oligomerization of HEXIM1 is a pre-
requisite for its incorporation into the LC and thus binding and
inhibition of P-TEFb in cells.
This work extends our earlier observations that the C-
terminus of HEXIM1 forms homodimers and also binds
CycT1 in vitro (16). However, in that study, HEXIM1 dimers
were not stable in the presence of CycT1, most likely because
7SK snRNA and its binding site on HEXIM1 were not pro-
vided. Notably, these ﬁndings are consistent with previous
reports on the C-terminus of HEXIM1, in which the N-
terminal 274 amino acids of HEXIM1 did not interact with
P-TEFb in the yeast two-hybrid assay, but the inclusion of
additional 26 residues to position 300 partly restored this bind-
ing (8,9). However, the precise mapping of the surfaces
involved in these protein–protein interactions and the role
of 7SK snRNA in this process had not been addressed. For
these reasons, we elected to move all our experiments into the
physiological setting of the cell, where we could examine our
mutations for binding and function in the same context and
correlate them to what has been surmised largely from bio-
chemical analyses. Importantly, our study provided further
details on surfaces involved in these interactions and presented
a kinetic picture of how the LC could be assembled. Namely, it
demonstrated the critical contribution of 7SK snRNA to the
formation of the stable LC. Combining deletions and clustered
point mutations also deﬁned these surfaces precisely, so that
we could distinguish between the oligomerization of HEXIM1
via CR2 and its binding to CycT1 and thus P-TEFb via CR1.
Since HEXIM1 oligomers do not bind P-TEFb in the absence
of 7SK snRNA, it is possible that the entire CR dictates their
self-association. In this scenario, the presence of 7SK snRNA
then provides the decisive oligomerization function, which
exposes CR1 for binding to CycT1, thus leading to the assem-
bly of the LC and P-TEFb inhibition. Importantly, our binding
studies were complemented with functional data, where we
examined wild-type and mutant HEXIM1 proteins for their
ability to block transcription directed by P-TEFb. First, we
used a plasmid target that depends uniquely on P-TEFb and
then we targeted P-TEFb to the promoter via a heterologous
DNA-tethering of CycT1 (17). Previously, we demonstrated
that this reporter and target are blocked by dominant negative
Cdk9 protein as well DRB or ﬂavopiridol, which are two ATP
analogs that inhibit the kinase activity of P-TEFb (17). Thus,
the assay depends critically on the catalytically active Cdk9
protein. In this way, we could distinguish directly between
HEXIM1 proteins that can and cannot inhibit P-TEFb and
correlate the formation of the LC with its functional con-
sequences in vivo.
A recent report demonstrated the formation of homo- and
hetero-oligomers between HEXIM1 and HEXIM2 proteins,
which were thought to be independent of 7SK snRNA (12).
Notably, our ﬁndings suggest that 7SK snRNA is pivotal in
directing the incorporation of HEXIM1 and HEXIM2 proteins
into the LC. These LCs with the homo- or hetero-oligomers of
HEXIM1/2 could subserve different physiological functions,
which would reﬂect different expression levels of these pro-
teins invarious tissuesandcells(7,12).Thissituationwouldbe
reminiscent of transcription factors with basic region-leucine
zippers (b/ZIP), where homo- and hetero-dimerizations via
coiled-coil regions modulate their transcriptional properties
(28,29). Although we refer to HEXIM1 oligomers throughout,
in vitro data (16) and glycerol gradient sedimentation analyses
(10) favor strongly the notion of HEXIM1 dimers. In addition,
the BR in HEXIM1 that resembles the arginine-rich motif in
Tat(27)couldbindthe topoftheﬁrststemloopin7SKsnRNA
that resembles the transactivation response (TAR) region in
HIV-1. In TAR, Tat and CycT1 bind the 50 bulge and central
loop as a heterodimer (30). Analogously, Tat from the equine
infectious anemia virus (EIAV) and equine CycT1 bind the
central loop in TAR from EIAV as a heterodimer (31). More-
over, the coat protein of bacteriophage MS2/R17 binds the
central loop of the operator as a homodimer, which gives it
greater afﬁnity and speciﬁcity (32,33). From these considera-
tions, we propose that HEXIM1 also forms homodimers on
7SK snRNA. These conclusions are supported by the calcu-
lated molecular mass of the LC, which is  500 kDa (10). This
size would encompass one molecule of 7SK snRNA, two
HEXIM1, two CycT1 and two Cdk9 proteins, for a ﬁnal
ratio of these subunits of 1:2:2:2.
When this manuscript was in preparation, two papers
describing HEXIM1 oligomerization were published (34,35).
In agreement with our conclusions, the oligomeric (most prob-
ably dimeric) nature of HEXIM1 was reported for free and
7SK snRNA-bound HEXIM1 in vitro and in vivo. Further-
more, the mutations of leucines at positions 287 and 294
were found to be sufﬁcient for the disruption of HEXIM1
dimerization using native gel electrophoresis in the absence
of 7SK snRNA in vitro (35). This discrepancy with our data
7008 Nucleic Acids Research, 2005, Vol. 33, No. 22could be explained by the usage of different leucine mutants in
our studies. Their mutations of leucines to positively charged
arginines could have more severe effects on dimer stability
than our mutations of leucines to non-polar alanines. Interest-
ingly, although their in vitro kinase assay revealed only minor
decreases in the inhibitory function of the mutant HEXIM1
L287, 294R protein, their analysis of this mutant protein in SC
andLCbyglycerolgradientcentrifugationclearly indicated its
absence from the LC in vivo (35). This ﬁnding corresponds
better to the decreased binding of our mutant f.Hex1mCR1
protein to CycT1 and disruption of its inhibitory function in
our in vivo experiments.
Finally, our study suggests a very dynamic picture for the
assembly and disassembly of the LC that dictates the overall
transcriptioninthe cell(7–13).Moreover,the balance between
the LC and SC is important to the organism as evidenced by
the genetic inactivation of HEXIM1 in the mouse that leads to
embryonic lethality due to cardiac hypertrophy (36). Addition-
ally, levels of HEXIM1 and P-TEFb are likely to play import-
ant roles in cellular activation, proliferation and
differentiation. These conclusions are revealed also by the
drug hexamethylene-bis-acetamide (HMBA), which is one
of the most potent differentiation agents, possibly due to its
effects on increased expression of HEXIM1 (12,18,37). More-
over, P-TEFb and HEXIM1 have now been implicated
in several cancers and their metastatic potential (38–41).
However, more studies are needed to deﬁne the precise
roles of these RNA–protein and protein–protein interactions
in these diseases. Thus, it is of great importance to determine
not only how LC and SC form but their dynamic interplay in
cells. To these ends, our study revealed the complex steps in
the assembly of the LC, which require 7SK snRNA to coord-
inate the oligomerization of HEXIM1 proteins and the correct
alignment of their C-termini so that they can bind P-TEFb,
resulting in its inhibition (Figure 8). Finer details of these
structures and the mechanism of P-TEFb inhibition will
come from NMR or crystallographic approaches. At the
same time, future studies will reveal the post-translational
modiﬁcations of the respective components that affect the
transition between the LC and SC.
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